The closely contested odds around 52.5% Yes for California Proposition 38 reflect voter weighing of potential advances in immunology and immunotherapy research for cancer, heart disease, and Alzheimer’s against the measure’s fiscal and structural features. The $8.4 billion general obligation bond would direct roughly half the funds to a single University of California-affiliated institute under narrow criteria, with the rest allocated via competitive grants, while requiring treatment price discounts and repayment from the state General Fund at an estimated $500 million annually for 25 years. Trader balance stems from support tied to research priorities amid federal funding pressures offset by scrutiny over concentrated allocation and long-term debt service. Recent polling trends, campaign spending disclosures, or shifts in state revenue projections could tip sentiment ahead of the November 3, 2026 vote.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
0% chance
NEW
NEW
Nov 3, 2026
0% chance
NEW
NEW
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).The closely contested odds around 52.5% Yes for California Proposition 38 reflect voter weighing of potential advances in immunology and immunotherapy research for cancer, heart disease, and Alzheimer’s against the measure’s fiscal and structural features. The $8.4 billion general obligation bond would direct roughly half the funds to a single University of California-affiliated institute under narrow criteria, with the rest allocated via competitive grants, while requiring treatment price discounts and repayment from the state General Fund at an estimated $500 million annually for 25 years. Trader balance stems from support tied to research priorities amid federal funding pressures offset by scrutiny over concentrated allocation and long-term debt service. Recent polling trends, campaign spending disclosures, or shifts in state revenue projections could tip sentiment ahead of the November 3, 2026 vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Market Opened: Jul 1, 2026, 6:33 PM ET
Volume
$2,851End Date
Nov 3, 2026Market Opened
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).The closely contested odds around 52.5% Yes for California Proposition 38 reflect voter weighing of potential advances in immunology and immunotherapy research for cancer, heart disease, and Alzheimer’s against the measure’s fiscal and structural features. The $8.4 billion general obligation bond would direct roughly half the funds to a single University of California-affiliated institute under narrow criteria, with the rest allocated via competitive grants, while requiring treatment price discounts and repayment from the state General Fund at an estimated $500 million annually for 25 years. Trader balance stems from support tied to research priorities amid federal funding pressures offset by scrutiny over concentrated allocation and long-term debt service. Recent polling trends, campaign spending disclosures, or shifts in state revenue projections could tip sentiment ahead of the November 3, 2026 vote.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
Volume
$2,851End Date
Nov 3, 2026Market Opened
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...The closely contested odds around 52.5% Yes for California Proposition 38 reflect voter weighing of potential advances in immunology and immunotherapy research for cancer, heart disease, and Alzheimer’s against the measure’s fiscal and structural features. The $8.4 billion general obligation bond would direct roughly half the funds to a single University of California-affiliated institute under narrow criteria, with the rest allocated via competitive grants, while requiring treatment price discounts and repayment from the state General Fund at an estimated $500 million annually for 25 years. Trader balance stems from support tied to research priorities amid federal funding pressures offset by scrutiny over concentrated allocation and long-term debt service. Recent polling trends, campaign spending disclosures, or shifts in state revenue projections could tip sentiment ahead of the November 3, 2026 vote.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions